Sienna Biopharmaceuticals Long Term Debt

Sienna Biopharmaceuticals's long-term debt stands at $0 as of September 2019. That compares with $30M in the prior-year period — down 100.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Sienna Biopharmaceuticals reported $0 in long-term debt versus $30M a year earlier — a 100.0% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $30M in the prior-year period — down 100.0% year over year. Sustained growth in long-term debt can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Sienna Biopharmaceuticals's long-term debt evolved across reporting periods, while the comparison chart places SNNAQ next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, long-term debt is commonly used to spot outliers. Sienna Biopharmaceuticals's reading of $0 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.